Alto Neuroscience, Inc.
ANRO · XNYSCIK 1999480fmd_0JZG1PPZZ4V87AHKWQA6P1SSRNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
Latest annual · FY2025
Millions- Operating income
- (66)
- Net income
- (63)
- Free cash flow
- (52)
Latest quarter · Q3 FY2026
Millions- Operating income
- (27)
- Net income
- (25)
- Free cash flow
- (21)
Daily close · ANROIEX trades only
Nov 09, 2026 to Nov 11, 2026 · 3 sessions31.19 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Alto Neuroscience, Inc. (ANRO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$66.4 million | -$68.6 million | 10-K 2026-03-16 · proof | |
| Net income | -$63.2 million | -$61.4 million | 10-K 2026-03-16 · proof | |
| Cash from operating activities | -$51.8 million | -$47.4 million | 10-K 2026-03-16 · proof | |
| Free cash flow | -$51.8 million | -$49.5 million | 10-K 2026-03-16 · proof | |
| Total assets | $184.7 million | $177.5 million | +4% | 10-K 2026-03-16 · proof |
| Total liabilities | $33.5 million | $26.1 million | +28.6% | 10-K 2026-03-16 · proof |
| Cash and cash equivalents | $176.5 million | $168.2 million | +4.9% | 10-K 2026-03-16 · proof |
| Total debt | $16.8 million | $10.3 million | +63.4% | 10-K 2026-03-16 · proof |
- What was Alto Neuroscience, Inc. (ANRO)'s operating income in fiscal 2025?
- Alto Neuroscience, Inc. (ANRO) reported operating income of -$66.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$68.6 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Alto Neuroscience, Inc. (ANRO)'s net income in fiscal 2025?
- Alto Neuroscience, Inc. (ANRO) reported net income of -$63.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$61.4 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Alto Neuroscience, Inc. (ANRO)'s cash from operating activities in fiscal 2025?
- Alto Neuroscience, Inc. (ANRO) reported cash from operating activities of -$51.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$47.4 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Alto Neuroscience, Inc. (ANRO)'s free cash flow in fiscal 2025?
- Alto Neuroscience, Inc. (ANRO) reported free cash flow of -$51.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$49.5 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Alto Neuroscience, Inc. (ANRO)'s total assets?
- As of Dec 31, 2025, Alto Neuroscience, Inc. (ANRO) reported total assets of $184.7 million, against $177.5 million a year earlier (+4%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Alto Neuroscience, Inc. (ANRO)'s total liabilities?
- As of Dec 31, 2025, Alto Neuroscience, Inc. (ANRO) reported total liabilities of $33.5 million, against $26.1 million a year earlier (+28.6%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Alto Neuroscience, Inc. (ANRO)'s cash and cash equivalents?
- As of Dec 31, 2025, Alto Neuroscience, Inc. (ANRO) reported cash and cash equivalents of $176.5 million, against $168.2 million a year earlier (+4.9%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What is Alto Neuroscience, Inc. (ANRO)'s total debt?
- As of Dec 31, 2025, Alto Neuroscience, Inc. (ANRO) reported total debt of $16.8 million, against $10.3 million a year earlier (+63.4%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ANRO&period_type=annual&limit=5"Information only, not investment advice.